Jennifer Angell

1.2k total citations
26 papers, 829 citations indexed

About

Jennifer Angell is a scholar working on Physiology, Organic Chemistry and Hematology. According to data from OpenAlex, Jennifer Angell has authored 26 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 8 papers in Organic Chemistry and 7 papers in Hematology. Recurrent topics in Jennifer Angell's work include Lysosomal Storage Disorders Research (13 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Carbohydrate Chemistry and Synthesis (7 papers). Jennifer Angell is often cited by papers focused on Lysosomal Storage Disorders Research (13 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Carbohydrate Chemistry and Synthesis (7 papers). Jennifer Angell collaborates with scholars based in United States, Argentina and Russia. Jennifer Angell's co-authors include Meryl S. LeBoff, Ghada El‐Hajj Fuleihan, Marı́a Elena Martı́nez, D. Trichopoulos, Chung‐Cheng Hsieh, Barry E. Rosenbloom, Leorah Ross, Marcia A. Testa, Elena Lukina and Ana Cristina Puga and has published in prestigious journals such as The Lancet, Blood and Journal of Bone and Mineral Research.

In The Last Decade

Jennifer Angell

26 papers receiving 797 citations

Peers

Countries citing papers authored by Jennifer Angell

Since Specialization

Citations

This map shows the geographic impact of Jennifer Angell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Angell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Angell more than expected).

Fields of papers citing papers by Jennifer Angell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Angell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Angell. The network helps show where Jennifer Angell may publish in the future.

Co-authorship network of co-authors of Jennifer Angell

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Angell. A scholar is included among the top collaborators of Jennifer Angell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Angell. Jennifer Angell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry 2016 ·Molecular Genetics and Metabolism Reports ·Jennifer Ibrahim, Lisa H. Underhill, John S. Taylor, Jennifer Angell, Michel Peterschmitt	12
2	Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial 2015 ·The Lancet ·Timothy M. Cox, Guillermo Drelichman, (unknown), Manisha Balwani, Thomas Andrew Burrow, Ana María Martins, Elena Lukina, Barry E. Rosenbloom, Leorah Ross, Jennifer Angell, Ana Cristina Puga	118
3	Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase in a real-world setting 2015 ·Molecular Genetics and Metabolism ·Michel Peterschmitt, John S. Taylor, Jennifer Angell, Jennifer Ibrahim	2
4	ENGAGE — A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: Results after 18months 2015 ·Molecular Genetics and Metabolism ·Pramod K. Mistry, Dominick Amato, Majed Dasouki, Seymour Packman, Gregory M. Pastores, Sarit Assouline, Manisha Balwani, Andres Ortega, Suma P. Shankar, María Helena Solano, Leorah Ross, Jennifer Angell, Michel Peterschmitt	8
5	Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment 2014 ·Blood Cells Molecules and Diseases ·Elena Lukina, Nora Watman, Marta Dragosky, Gregory M. Pastores, Elsa Ávila Arreguin, Hanna Rosenbaum, Ari Zimran, Jennifer Angell, Leorah Ross, Ana Cristina Puga, (unknown)	61
6	Eliglustat safety profile based on a pooled analysis of data from four trials in Gaucher disease type I 2014 ·Molecular Genetics and Metabolism ·Leorah Ross, (unknown), Ana Cristina Puga, Gerald F. Cox, Sachin Marulkar, Jennifer Angell, (unknown), Raymond Mankoski	4
7	ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals 2014 ·Molecular Genetics and Metabolism ·Timothy M. Cox, Guillermo Drelichman, (unknown), Manisha Balwani, Thomas Andrew Burrow, Ana Maria Martins, Elena Lukina, Barry E. Rosenbloom, Leorah Ross, Jennifer Angell, Ana Cristina Puga	1
8	Encore: A Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat To Imiglucerase In Gaucher Disease Type 1 Patients On Enzyme Replacement Therapy Who Have Reached Therapeutic Goals 2013 ·Blood ·Manisha Balwani, Timothy M. Cox, Guillermo Drelichman, (unknown), Ana María Martins, Elena Lukina, Barry E. Rosenbloom, Leorah Ross, Jennifer Angell, Ana Cristina Puga	5
9	Plerixafor Plus Granulocyte Colony-Stimulating Factor Improves the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma and Low Circulating Peripheral Blood CD34+ Cells 2013 ·Biology of Blood and Marrow Transplantation ·Richard T. Maziarz, Auayporn Nademanee, Ivana N. Micallef, Patrick J. Stiff, Gary Calandra, Jennifer Angell, John F. DiPersio, Brian J. Bolwell	34
10	Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil®) + G-CSF In Pediatric Patients with Malignant Disorders 2010 ·Blood ·Shalini Shenoy, Barbara L. Asselin, Jignesh Dalal, Rakesh K. Goyal, Jonathan L. Kaufman, David M. Loeb, John M. McCarty, Kent A. Robertson, Caron Strahlendorf, Mark C. Walters, Jennifer Angell, Dirk Huebner, Peter J. Shaw	2
11	Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study 2008 ·Clinical Genetics ·(unknown), GM Pastores, (unknown), J. A. Barranger, (unknown), Seymour Packman, Paige Kaplan, Henry J. Mankin, Ramnik J. Xavier, Jennifer Angell, (unknown), Daniel I. Rosenthal	95
12	Imiglucerase (Cerezyme^®) improves quality of life in patients with skeletal manifestations of Gaucher disease 2007 ·Clinical Genetics ·Neal J. Weinreb, J. A. Barranger, Seymour Packman, Ainu Prakash‐Cheng, Barry E. Rosenbloom, Katherine B. Sims, Jennifer Angell, Alison Skrinar, GM Pastores	76
13	Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study. 2007 ·Blood ·Ivana N. Micallef, Patrick J. Stiff, John F. DiPersio, Richard T. Maziarz, John M. McCarty, Jennifer Angell, Gary Bridger, Gary Calandra, (unknown)	12
14	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation. 2007 ·Blood ·John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee, Patrick J. Stiff, Ivana N. Micallef, Jennifer Angell, Gary Bridger, Gary Calandra, (unknown)	23
15	Calcidiol and PTH Levels in Women Attending an Osteoporosis Program 1999 ·Calcified Tissue International ·Susan T. Haden, Ghada El‐Hajj Fuleihan, Jennifer Angell, (unknown), Meryl S. LeBoff	49
16	Monitoring Therapeutic Response in Skeletal Metastases Using Dual-Energy X-Ray Absorptiometry: A Prospective Feasibility Study in Breast Cancer Patients 1999 ·Cancer Investigation ·Charles L. Shapiro, Jennifer L. Keating, Jennifer Angell, Milos J. Janicek, Rebecca Gelman, Daniel M. Hayes, Meryl S. LeBoff	19
17	Longitudinal Changes in Bone Density in Hyperparathyroidism 1999 ·Journal of Clinical Densitometry ·Ghada El‐Hajj Fuleihan, Francis D. Moore, Meryl S. LeBoff, (unknown), Caren M. Gundberg, Jennifer Angell, Jennifer Scott	16
18	Olive Oil and Human Cancer: An Assessment of the Evidence 1997 ·Preventive Medicine ·(unknown), Marı́a Elena Martı́nez, Jennifer Angell, Chung‐Cheng Hsieh, D. Trichopoulos	129
19	Reproducibility of DXA absorptiometry: A model for bone loss estimates 1995 ·Journal of Bone and Mineral Research ·Ghada El‐Hajj Fuleihan, Marcia A. Testa, Jennifer Angell, (unknown), Meryl S. LeBoff	89
20	Dual-energy X-ray absorptiometry of the forearm: Reproducibility and correlation with single-photon absorptiometry 1992 ·Journal of Bone and Mineral Research ·Meryl S. LeBoff, Ghada El‐Hajj Fuleihan, Jennifer Angell, (unknown), Kate Curtis	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact